P487 THE NEW PCSK9–INHIBITOR INCLISIRAN: AN EXCEPTIONAL REDUCTION IN LDL CHOLESTEROL FROM THE FIRST PATIENTS OF THE NIGUARDA HOSPITAL [PDF]
, 2023 Aurélie Merlo +8 more
openalex +1 more source
Therapeutic Inertia in Dyslipidemia Management for Secondary Cardiovascular Prevention: Results from the Italian ITACARE-P Network [PDF]
: Background/Objectives: This study assessed the proportion of secondary cardiovascular prevention patients who achieved low-density lipoprotein (LDL) cholesterol targets as per the 2019 ESC/EAS Dyslipidemia Guidelines.
Ambrosetti, Marco +18 more
core +1 more source
A Randomised Study to Evaluate the Effect of an “Inclisiran First” Implementation Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated Lowdensity Lipoprotein Cholesterol: Rationale & Design of the VICTORION-INITIATE Trial [PDF]
, 2023 openalex +1 more source
7-016 Efficacy of Inclisiran in patients post myocardial infarction with high total cholesterol and LDL levels and intolerance to statins [PDF]
Yi Lung Gan +5 more
openalex +1 more source
New hope for hyperlipidemia management: Inclisiran [PDF]
Journal of Cardiology, 2018 Dhrubajyoti Bandyopadhyay +4 more
openaire +2 more sources
Inclisiran for the treatment of hypercholesterolaemia: implications and unanswered questions from the ORION trials [PDF]
, 2020 Arjen J. Cupido, John J.P. Kastelein
openalex +1 more source
Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment [PDF]
, 2022 David Kallend +4 more
openalex +1 more source
PCSK9 inhibitors – new era of dyslipidemia treatment - effectiveness in reducing low-density lipoprotein (LDL-C) and cardiovascular risk [PDF]
Introduction: Abnormal blood cholesterol levels in patients with increased cardiovascular risk have a worse prognosis for patient survival. Treating dyslipidemia is important because it can improve patient comfort and safety.
Bodera, Magdalena +7 more
core +1 more source
Lipid-lowering approaches to manage statin-intolerant patients [PDF]
Statins have improved the potential to prevent cardiovascular disease events and to prolong the lives of patients. Statins, among the most widely used drugs worldwide, reduce the levels of low-density lipoprotein cholesterol (LDL-C) by an average of 30 ...
Bertoletti, Alessandra +5 more
core +1 more source
Inclisiran: A Systematic Review Exploring the Revolutionary Approach of Twice-Yearly Dosing Regimen in the Treatment of Hypercholesterolemia [PDF]
Sanjana Singareddy +6 more
openalex +1 more source